University of Ulsan College of Medicine Researcher Publishes New Study Findings on Gastric Cancer (Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival...).

A recent study conducted by researchers at the University of Ulsan College of Medicine in Seoul, South Korea, has found that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improves overall survival (OS) and progression-free survival (PFS) in patients with resectable locally advanced gastric cancer (LAGC). The study compared the outcomes of patients treated with CSC versus surgery followed by adjuvant S-1 (SC). The results showed that CSC significantly increased OS and improved PFS compared to SC. The researchers concluded that neoadjuvant DOS chemotherapy should be considered as a standard treatment option for Asian patients with LAGC. [Extracted from the article]